ARCA biopharma Announces US FDA Acceptance of Gencaro IND Application for the Treatment of Atrial Fibrillation

Phase 2B/3 GENETIC-AF Trial on Track to Begin Patient Enrollment in Q1 2014

Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment

ARCA biopharma, Inc. (ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the Company’s Gencaro^TM Investigational New Drug (IND) application for atrial fibrillation (AF) has been accepted by the U.S. Food and Drug Administration (FDA) and is now active.

Conatus Pharmaceuticals Receives U.S. Orphan Drug Designation for Emricasan for Treatment of Liver Transplant Recipients With Reestablished Fibrosis

Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Conatus' drug candidate emricasan for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The FDA's Orphan Drug Designation program is intended to encourage the development of drugs and biologics that may provide benefit to patients suffering from rare diseases or conditions.

OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients

Celgene Invests in OncoMed's Demcizumab and up to Five Additional Preclinical Biologics Programs; OncoMed Leads Early Clinical Trials and Retains Co-Development, Co-Commercialization and Profit-Sharing Rights

OncoMed to Receive $177.25 Million Upfront, Including a $22.25 Million Equity Investment

OncoMed Pharmaceuticals, Inc. (OMED) and Celgene Corporation (CELG) today announced an agreement to jointly develop and commercialize up to six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4).

NovaBay Pharmaceuticals Announces Publication of Novel Surgical Procedure for Life Threatening Wounds and Flesh Eating Bacteria

New Procedure Utilizes Adjunctive NeutroPhase® Therapy

Paper in the Medical Journal WOUNDS Describes First Successful Procedure that Removes Toxins from Wounds with Less Invasive Debridement and Avoids Possible Amputation

NovaBay^® Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced the publication of a scientific paper by Dr. John R. Crew of Seton Medical Center, Daly City, California, describing the first use of adjunctive NeutroPhase^®* irrigation therapy in conjunction with Negative Pressure Wound Therapy (NPWT) to successfully manage the severely-infected wound in the arm of a patient with life-threatening ‘flesh-eating’ disease.